Teri Klein

Nowadays, Teri Klein has become a relevant topic in various areas of society. Its impact has been felt in politics, the economy, culture and people's daily lives. Since its emergence, Teri Klein has aroused great interest and has generated debates and discussions around its scope and consequences. This article seeks to explore the multiple facets of Teri Klein, analyzing its influence in different contexts and offering a comprehensive view of its importance in the current landscape. Through a multidisciplinary approach, we aim to address Teri Klein from different perspectives, thus contributing to a broader and enriching understanding of this phenomenon.

Teri E. Klein
Alma materUniversity of California, Santa Cruz
UCSF
AwardsFellow of the American College of Medical Informatics (2001)[1]
Fellow of the American Association for the Advancement of Science (2021)[2]
Scientific career
FieldsPharmacogenomics
InstitutionsStanford University
ThesisKARMA, a knowledge-based system for receptor mapping (1987)
Websiteprofiles.stanford.edu/teri-klein

Teri E. Klein is an American professor of Biomedical Data Science and Medicine (and of Genetics, by courtesy) at Stanford University. She is known for her work on pharmacogenomics and computational biology.[3]

Education

Klein has a B.A. from the University of California, Santa Cruz (1980) and a Ph.D. from the University of California, San Francisco (1987). In 2000 she started a position at Stanford University[4] where, as of 2022, she holds the position of professor (research).[5]

She is a co-founder of the Pacific Symposium on Biocomputing and is a Principal Investigator for PharmGKB, Clinical Pharmacogenomics Implementation Consortium (CPIC), The Pharmacogenomic Clinical Annotation Tool (PharmCAT), and Clinical Genome Resource (ClinGen).[6]

Selected publications

  • Chen, Rui; Mias, George I.; Li-Pook-Than, Jennifer; Jiang, Lihua; Lam, Hugo Y. K.; Chen, Rong; Miriami, Elana; Karczewski, Konrad J.; Hariharan, Manoj; Dewey, Frederick E.; Cheng, Yong; Clark, Michael J.; Im, Hogune; Habegger, Lukas; Balasubramanian, Suganthi (2012-03-16). "Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes". Cell. 148 (6): 1293–1307. doi:10.1016/j.cell.2012.02.009. ISSN 0092-8674. PMC 3341616. PMID 22424236.
  • Whirl-Carrillo, M; McDonagh, E M; Hebert, J M; Gong, L; Sangkuhl, K; Thorn, C F; Altman, R B; Klein, T E (2012). "Pharmacogenomics Knowledge for Personalized Medicine". Clinical Pharmacology & Therapeutics. 92 (4): 414–417. doi:10.1038/clpt.2012.96. ISSN 0009-9236. PMC 3660037. PMID 22992668.
  • Gammal, Roseann S.; Caudle, Kelly E.; Klein, Teri E.; Relling, Mary V. (2019). "Considerations for pharmacogenomic testing in a health system". Genetics in Medicine. 21 (8): 1886–1887. doi:10.1038/s41436-018-0421-x. ISSN 1530-0366. PMID 30631112. S2CID 58004988.
  • Gong, Li; Whirl-Carrillo, Michelle; Klein, Teri E. (2021). "PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge". Current Protocols. 1 (8): e226. doi:10.1002/cpz1.226. ISSN 2691-1299. PMC 8650697. PMID 34387941.

Awards and honors

Klein was named a fellow of the American College of Medical Informatics in 2001.[4] In 2021, she was named a fellow of the American Association for the Advancement of Science.[2]

References

  1. ^ "Teri E. Klein, PhD, Fellow of the American College of Medical Informatics".
  2. ^ a b "2021 AAAS Fellows".
  3. ^ "Report of the president: Academic Council Professoriate appointments". news.stanford.edu. Retrieved 2025-03-29.
  4. ^ a b "Fellows of ACMI". AMIA - American Medical Informatics Association. Retrieved 2022-10-26.
  5. ^ "Teri Klein". www.ncbi.nlm.nih.gov. Retrieved 2022-10-26.
  6. ^ "Stanford awarded NIH funding to support ClinGen efforts in pharmacogenomics, autoimmune diseases, and ancestry and diversity in genetic research". October 5, 2021. Retrieved 2022-03-29.